HONG KONG – Brii Biosciences has entered into two significant partnerships to expand its pipeline. The first is a license and collaboration agreement with VBI Vaccines Ltd. and Vir Biotechnology Inc. focused on hepatitis B virus (HBV) infection. Brii Bio licensed greater China rights, which includes the Chinese mainland, Hong Kong, Macau and Taiwan, for a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in a deal that could be worth up to $129 million plus royalties. Read More
Revance Therapeutics Inc. has never made a secret of its goal to build a better Botox. The Newark, Calif.-based company is making swift progress to reach that target as it prepares to file a BLA for lead program RT-002, an injectable formulation of daxibotulinumtoxinA, in moderate to severe glabellar lines after moving RT-002 into a pivotal phase III to treat cervical dystonia. Read More
TOKYO – Defying the non-litigious nature of Japanese companies, makers of drugs and biosimilars are increasingly willing to file lawsuits to protect patents or clear the way to market biosimilars. Read More
SAN DIEGO – First-line treatment of peripheral T-cell lymphomas (PTCL) with a quartet of drugs substituting Adcetris (brentuximab vedotin) for Oncovin (vincristine) in the decades-old standard of care for the disease, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), proved superior on both progression-free survival and overall survival, according to full data reported Tuesday by Seattle Genetics Inc. and partner Takeda Pharmaceutical Co. Ltd. Read More
HONG KONG – In just seven months, Singapore-based biotech company Tychan Pte Ltd. has moved its monoclonal antibody, TY-014, from initiation and into clinical development. Read More
Changzhou Qianhong Bio-pharma Co. Ltd., of Changzhou, China, said it started phase two construction of its pharmaceuticals production facility at Changzhou National Hi-tech District involving an investment of ¥1 billion (US$145.8 million). The facility will focus on the research and development of innovative and first-of-its-class-in-China biological drugs. Read More
